DH376
A laboratory probe that blocks 2-AG production (a diacylglycerol lipase inhibitor).
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₃₁H₂₈F₂N₄O₃
CID 129188688
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 542.60 g/mol
Updated on
In plain terms
DH376 is a laboratory molecule, not a cannabinoid from hemp. It blocks the enzyme that makes 2-AG, a substance the body produces itself and that acts on the same receptors as THC. Researchers use it on cells and in animals to understand the role of this signal; it is not a consumer product.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to DH376: one ring per factor of 100. A target with no measured value stays on the edge.
Cited values
- DAGLαInhibitorIC50 = 6 nM · human70 out of 100
Ogasawara et al., PNAS 2016 (new tab) · recombinant human DAGLα (HEK293T cell lysates), conversion of the SAG substrate to 2-AG; 0.5 to 1.2 nM in ABPP profiling
- DAGLβInhibitorno measured value cited
- ABHD6Inhibitorno measured value cited
- PLA2G7Inhibitorno measured value cited
Pharmacology
DH376 is a 1,2,3-triazole urea, a chemical probe of the endocannabinoid system that covalently and irreversibly inhibits diacylglycerol lipases α and β, the enzymes that synthesise 2-AG (Ogasawara et al. 2016). Its IC50 is 6 nM on recombinant human DAGLα and 3 to 8 nM on DAGLβ. In mice, intraperitoneal injection of 3 to 50 mg/kg blocked brain DAGLα activity in a dose-dependent manner (ED50 of 5 to 10 mg/kg, full inhibition at 30-50 mg/kg), with inhibition lasting up to 8 h at 50 mg/kg and partial recovery at 24 h. Within 2 h, DAGL blockade reorganised bioactive brain lipids (higher diacylglycerols, lower 2-AG, anandamide, arachidonic acid and the prostaglandins PGD2 and PGE2), abolished most of two CB1-dependent forms of synaptic plasticity in brain slices (cerebellar DSE and hippocampal DSI) and attenuated lipopolysaccharide-induced anapyrexia. Deng et al. (2017) describe the molecule as a picomolar-activity inhibitor; in fasted mice it temporarily reduced refeeding, as did DO34 but also the control DO53, which does not inhibit DAGLs: the authors conclude that triazole ureas may affect energy balance through several targets. All these data are preclinical.
Key sources.
- Ogasawara D et al., Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition, PNAS 2016;113(1):26-33 (new tab)PMID 26668358
- Deng H et al., Triazole Ureas Act as Diacylglycerol Lipase Inhibitors and Prevent Fasting-Induced Refeeding, Journal of Medicinal Chemistry, 2017, 60(1), 428-440 (new tab)PMID 27992221
- ANSM, Consolidated list of substances classified as narcotics, updated 16 February 2026, annex IV (new tab)
- PubChem, compound record CID 129188688 (DH376) (new tab)
History
- Source
- A synthetic molecule of the 1,2,3-triazole urea class, absent from cannabis and from any living organism. A chemical probe distributed as a research reagent.
Origin
Research tool
No biosynthetic pathway: a synthetic molecule of the 1,2,3-triazole urea class.
Legal framework
- European Union
A laboratory reagent; no European Union classification specific to the molecule was found in the sources consulted. Its status depends on the national law of each Member State.
- France
Not classified: absent from the ANSM list of narcotics (consolidated version updated 16/02/2026). A triazole urea combined with a piperidine, unrelated to the benzo[c]chromene nucleus or to indole, indazole or pyrrole nuclei, it falls under none of the generic entries of Annex IV. The absence of classification is not a marketing authorisation.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
No dedicated article.
References
- Ogasawara D et al., Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition, PNAS 2016;113(1):26-33 (new tab)PMID 26668358
- Deng H et al., Triazole Ureas Act as Diacylglycerol Lipase Inhibitors and Prevent Fasting-Induced Refeeding, Journal of Medicinal Chemistry, 2017, 60(1), 428-440 (new tab)PMID 27992221
- ANSM, Consolidated list of substances classified as narcotics, updated 16 February 2026, annex IV (new tab)
- PubChem, compound record CID 129188688 (DH376) (new tab)
Identifiers
Names
- IUPAC name
- [(2R,5R)-2-benzyl-5-prop-2-ynoxypiperidin-1-yl]-[4-[bis(4-fluorophenyl)-hydroxymethyl]triazol-2-yl]methanone
- Other names
- DH-376
Identifiers
- Formula
- C₃₁H₂₈F₂N₄O₃
- PubChem CID
- 129188688(new tab)
- InChIKey
- GVLOFRPVRYAFKI-VSGBNLITSA-N
- SMILES
- C#CCO[C@@H]
1CC[C@@H] (N(C1) C(= O) N2N= CC(= N2) C(C3= CC= C(C= C3) F) (C4= CC= C(C= C4) F) O) CC5= CC= CC= C5
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.